TPIDB > 臨床試驗主持人
臨床試驗主持人
發表文獻
53筆
1
Hsiao CY, Teng X, Su TH, Lee PH, Kao JH, Huang KW. Improved second harmonic generation and two-photon excitation fluorescence microscopy-based quantitative assessments of liver fibrosis through auto-correction and optimal sampling. Quant Imaging Med Surg. 2021 Jan;11(1):351-361. doi: 10.21037/qims-20-394. PMID: 33392034; PMCID: PMC7719928.
2
Su TH, Hsu SJ, Kao JH. Systemic therapy for hepatocellular carcinoma: New agents and therapeutic hierarchy. J Formos Med Assoc. 2021 Aug 25:S0929-6646(21)00394-6. doi: 10.1016/j.jfma.2021.08.018. Epub ahead of print. PMID: 34454796.
3
Liu M, Tseng TC, Jun DW, Yeh ML, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung M, Toyoda H, Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HI, Nguyen MH. Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. Hepatol Int. 2021 Feb;15(1):71-81. doi: 10.1007/s12072-020-10113-2. Epub 2021 Jan 4. PMID: 33394321.
4
Yeh ML, Hung CH, Tseng KC, Lai HC, Chen CY, Kuo HT, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Huang CF, Huang JF, Dai CY, Chuang WL, Tsai PC, Peng CY, Liu CJ, Yu ML. Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). Hepatol Int. 2021 Aug 7. doi: 10.1007/s12072-021-10220-8. Epub ahead of print. PMID: 34365587.
5
Tseng TC, Choi J, Nguyen MH, Peng CY, Siakavellas S, Papatheodoridis G, Wang CC, Lim YS, Lai HC, Trinh HN, Wong C, Wong C, Zhang J, Li J, Kao JH. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. Hepatol Int. 2021 Feb;15(1):105-113. doi: 10.1007/s12072-020-10124-z. Epub 2021 Feb 5. PMID: 33547557; PMCID: PMC7863859.
6
Su TH, Peng CY, Chang SH, Tseng TC, Liu CJ, Chen CL, Liu CH, Yang HC, Chen PJ, Kao JH. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. J Formos Med Assoc. 2021 Aug 24:S0929-6646(21)00361-2. doi: 10.1016/j.jfma.2021.08.003. Epub ahead of print. PMID: 34452785.
7
Wu CH, Liang PC, Su TH, Lin MC, Chang YH, Shih TT, Kao JH. Iodized oil computed tomography versus ultrasound-guided radiofrequency ablation for early hepatocellular carcinoma. Hepatol Int. 2021 Aug 2. doi: 10.1007/s12072-021-10236-0. Epub ahead of print. PMID: 34338971.
8
Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int. 2021 Aug;15(4):833-851. doi: 10.1007/s12072-021-10223-5. Epub 2021 Jul 23. PMID: 34297329.
9
Chen CY, Huang CF, Cheng PN, Tseng KC, Lo CC, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Huang JF, Yang CC, Hu JT, Lin CW, Chen CT, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Mo LR, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao CN, Tsai PC, Liu CH, Lee MH, Liu CJ, Dai CY, Kao JH, Chuang WL, Lin HC, Yu ML. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int. 2021 Jun;41(6):1265-1277. doi: 10.1111/liv.14849. Epub 2021 Mar 12. PMID: 33655714; PMCID: PMC8252422.
10
Liu CH, Chen PY, Chen JJ, Lo CC, Su WW, Tseng KC, Liu CJ, Huang CS, Huang KJ, Yang SS, Peng CY, Tsai MC, Kao WY, Chang CY, Shih YL, Fang YJ, Chen CY, Lee PL, Huang JJ, Su PY, Tseng CW, Hung CC, Chang CH, Huang YJ, Lai HC, Chang CC, Lee FJ, Hsieh TY, Kao JH. Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan. Hepatol Int. 2021 Apr;15(2):338-349. doi: 10.1007/s12072-021-10158-x. Epub 2021 Mar 6. PMID: 33677787.
